Large-scale comparative analyses of immunomarkers for diagnostic subtyping of non-small-cell lung cancer biopsies

Histopathology

Volumn 61, Issue 6, 2012, Pages 1017-1025

  Warth, Arne ^a   Muley, Thomas ^b   Herpel, Esther ^a   Meister, Michael ^b   Herth, Felix J F ^c   Schirmacher, Peter ^a   Weichert, Wilko ^a   Hoffmann, Hans ^c   Schnabel, Philipp A ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c NONE   (Germany)

Author keywords

Biopsy; Immunohistochemistry; Non small cell lung cancer; Not otherwise specified; Subtyping

Indexed keywords

BIOLOGICAL MARKER; CYTOKERATIN 5; CYTOKERATIN 6; CYTOKERATIN 7; DESMOCOLLIN; DESMOCOLLIN 3; NAPSIN A; PROTEIN; PROTEIN P63; THYROID TRANSCRIPTION FACTOR 1; UNCLASSIFIED DRUG;

ARTICLE; DIAGNOSTIC VALUE; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RELIABILITY; SENSITIVITY AND SPECIFICITY; TUMOR BIOPSY;

ADENOCARCINOMA; ALGORITHMS; BIOLOGICAL MARKERS; BIOPSY; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; DIAGNOSIS, DIFFERENTIAL; HUMANS; KERATIN-5; KERATIN-6; KERATIN-7; LUNG NEOPLASMS; MEMBRANE PROTEINS; NUCLEAR PROTEINS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TRANSCRIPTION FACTORS;

EID: 84870391117     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2012.04308.x     Document Type: Article

References (30)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J. Clin. 2010; 60; 277-300.
2. Rossi A, Maione P, Bareschino MA et al. The emerging role of histology in the choice of first-line treatment of advanced non-small cell lung cancer: implication in the clinical decision-making. Curr. Med. Chem. 2010; 17; 1030-1038.
3. Scagliotti G, Hanna N, Fossella F et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist 2009; 14; 253-263.
4. Johnson DH, Fehrenbacher L, Novotny WF et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J. Clin. Oncol. 2004; 22; 2184-2191.
5. Cohen MH, Gootenberg J, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist 2007; 12; 713-718.
6. Maemondo M, Inoue A, Kobayashi K et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med. 2010; 362; 2380-2388.
7. Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 2009; 361; 947-957.
8. Soda M, Choi YL, Enomoto M et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448; 561-566.
9. Kwak EL, Bang YJ, Camidge DR et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 2010; 363; 1693-1703.
10. Karp DD, Paz-Ares LG, Novello S et al. Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751, 871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J. Clin. Oncol. 2009; 27; 2516-2522.
11. Corral J, Lopez-Villalobos JL, Gomez-Izquierdo L, Borrego I, Paz-Ares L. Pathologic complete responses after chemotherapy plus figitumumab in stage IV non-small-cell lung cancer. J. Clin. Oncol. 2011; 29; e163-e165.
12. Travis WD, Brambilla E, Noguchi M et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J. Thorac. Oncol. 2011; 6; 244-285.
13. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC. World Health Organization classification of tumors. Pathology and genetics. Tumours of the lung, pleura, thymus and heart. Lyon: IARC Press, 2004.
14. Terry J, Leung S, Laskin J, Leslie KO, Gown AM, Ionescu DN. Optimal immunohistochemical markers for distinguishing lung adenocarcinomas from squamous cell carcinomas in small tumor samples. Am. J. Surg. Pathol. 2010; 34; 1805-1811.
15. Edwards SL, Roberts C, McKean ME, Cockburn JS, Jeffrey RR, Kerr KM. Preoperative histological classification of primary lung cancer: accuracy of diagnosis and use of the non-small cell category. J. Clin. Pathol. 2000; 53; 537-540.
16. Scagliotti GV, Parikh P, von Pawel J et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J. Clin. Oncol. 2008; 26; 3543-3551.
17. Motoi N, Szoke J, Riely GJ et al. Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am. J. Surg. Pathol. 2008; 32; 810-827.
18. Yatabe Y, Mitsudomi T, Takahashi T. TTF-1 expression in pulmonary adenocarcinomas. Am. J. Surg. Pathol. 2002; 26; 767-773.
19. Lau SK, Luthringer DJ, Eisen RN. Thyroid transcription factor-1: a review. Appl. Immunohistochem. Mol. Morphol. 2002; 10; 97-102.
20. Loo PS, Thomas SC, Nicolson MC, Fyfe MN, Kerr KM. Subtyping of undifferentiated non-small cell carcinomas in bronchial biopsy specimens. J. Thorac. Oncol. 2010; 5; 442-447.
21. Nicholson AG, Gonzalez D, Shah P et al. Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5/6, and P63, and EGFR mutation analysis. J. Thorac. Oncol. 2010; 5; 436-441.
22. Camilo R, Capelozzi VL, Siqueira SA, Del Carlo Bernardi F. Expression of p63, keratin 5/6, keratin 7, and surfactant-A in non-small cell lung carcinomas. Hum. Pathol. 2006; 37; 542-546.
23. Wu M, Wang B, Gil J et al. P63 and TTF-1 immunostaining. A useful marker panel for distinguishing small cell carcinoma of lung from poorly differentiated squamous cell carcinoma of lung. Am. J. Clin. Pathol. 2003; 119; 696-702.
24. Chu PG, Weiss LM. Expression of cytokeratin 5/6 in epithelial neoplasms: an immunohistochemical study of 509 cases. Mod. Pathol. 2002; 15; 6-10.
25. Kargi A, Gurel D, Tuna B. The diagnostic value of TTF-1, CK 5/6, and p63 immunostaining in classification of lung carcinomas. Appl. Immunohistochem. Mol. Morphol. 2007; 15; 415-420.
26. Khayyata S, Yun S, Pasha T et al. Value of P63 and CK5/6 in distinguishing squamous cell carcinoma from adenocarcinoma in lung fine-needle aspiration specimens. Diagn. Cytopathol. 2009; 37; 178-183.
27. Au NH, Gown AM, Cheang M et al. P63 expression in lung carcinoma: a tissue microarray study of 408 cases. Appl. Immunohistochem. Mol. Morphol. 2004; 12; 240-247.
28. Chu P, Wu E, Weiss LM. Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases. Mod. Pathol. 2000; 13; 962-972.
29. Bishop JA, Sharma R, Illei PB. Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma. Hum. Pathol. 2010; 41; 20-25.
30. Monica V, Ceppi P, Righi L et al. Desmocollin-3: a new marker of squamous differentiation in undifferentiated large-cell carcinoma of the lung. Mod. Pathol. 2009; 22; 709-717.